Below you find publications from our own reportserie available in English, all are free for download as pdf files. To see all of our publications visit our Swedish website.
Improving outcomes for women with triple-negative breast cancer in Asia-Pacific
IHE Report 2023:3, IHE: Lund, Sweden
Improving the care of women with triple-negative breast cancer
IHE Report 2023:2, IHE: Lund, Sweden
The economic burden of overweight and obesity in Swedish children – A lifetime perspective
IHE Report 2022:12, IHE: Lund, Sweden
Cancer Care in Türkiye in a European Context
IHE Report 2022:10, IHE: Lund, Sweden
The importance of perspective when eliciting preferences for health – A study of the willingness to pay for hepatitis C treatment
IHE Report 2022:7, IHE: Lund, Sweden
Comparator Report on Cancer in Ireland – Disease Burden, Costs and Access to Medicines
IHE Report 2022:4, IHE: Lund, Sweden
Diagnosed but not treated: How to improve patient access to advanced NSCLC treatment in Europe
IHE Report 2022:2, IHE: Lund, Sweden
Cancer Care in the Middle East and Africa
IHE Report 2021:9, Lund, Sweden
Cancer care and access to cancer drugs in Asia-Pacific – Main report
IHE Report 2021:3, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P
Pricing policies for off-patent drugs in Asia-Pacific
IHE Report 2021:3g, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P
Health spending on cancer drugs and unmet patient needs in Asia-Pacific
IHE Report 2021:3f, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P
Patient access to innovative cancer drugs in Asia-Pacific
IHE Report 2021:3e, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P
Health spending on cancer in Asia-Pacific
IHE Report 2021:3d, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P
The burden of cancer in Asia-Pacific
IHE Report 2021:3c, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P
Cancer care and access to cancer drugs in Asia-Pacific – Executive summary
IHE Report 2021:3b, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P
Cancer care and access to cancer drugs in Asia-Pacific – Introduction
IHE Report 2021:3a, IHE: Lund, Sweden
Persson U, Olofsson S, Keel G
Disease burden associated with Covid-19 in Sweden – QALYs lost due to excess mortality
Lund, Sweden: IHE Report 2020:8
Persson U, Olofsson S, Yan Gu N, Gong C L, Jiao X and Hay J
Quality-of-Life in the Swedish general population during Covid-19 – based on measurement pre- and post pandemic outbreak
Lund, Sweden: IHE Report 2020:7
Hofmarcher T, Lindgren P
The Cost of Cancers of the Digestive System in Europe
Lund, Sweden: IHE Report 2020:6
Persson U, Norlin J
Opportunities and challenges of an innovative payment model for Advanced Therapy Medicinal Products in Sweden -A hypothetical example in the treatment of β-thalassemia
Lund, Sweden: IHE Report 2020:3
Löfvendahl S & Steen Carlsson K
Patient pathways in the treatment of opioid drug dependency – A register-based real world analysis using regional healthcare registers
Lund, Sweden: IHE Report 2020:2
Hofmarcher T, Brådvik G, Svedman C, Lindgren P, Jönsson B & Wilking N
Comparator Report on Cancer in Europe 2019 – Disease Burden, Costs and Access to Medicines
Lund, Sweden: IHE Report 2019:7
Jönsson B, Kobelt G, Motlagh A, Wilking U & Wilking N
An assessment of breast cancer and its management in Iran
Lund, Sweden: IHE Report 2019:3
Hofmarcher T, Brådvik G, Lindgren P, Jönsson B & Wilking N
Comparator Report on Cancer in the Nordic Countries – Disease Burden, Costs and Access to Medicines
Lund, Sweden: IHE Report 2019:2a (Summary)
Lund, Sweden: IHE Report 2019:2b
Norlin J, Althin A, Schmitt-Egenolf M & Persson U
An outcome-based payment model for biologic agents in psoriasis
Lund, Sweden: IHE Report 2018:2
Jönsson B, Hofmarcher T, Lindgren P, Moen F & Wilking N
Comparator Report on Patient Access to Cancer Medicines in Europe Revisited- A UK Perspective
Lund, Sweden: IHE Report 2017:1
Persson U, Steen Carlsson K and Jönsson B
Alternative Payment Models in Haemophilia Treatment
Lund, Sweden: IHE Report 2016:10
Lundqvist A, Andersson E and Steen Carlsson K
The costs of diabetes in 2020 and 2030 − A model analysis comparing innovative glucose lowering treatments in second line following European and American guidelines compared to current standard of care
Lund, Sweden: IHE Report 2016:9
Jönsson B, Hofmarcher T, Lindgren P and Wilking N
Comparator report on patient access to cancer medicines in Europe revisited
Lund, Sweden: IHE Report 2016:4
Jönsson B, Persson U and Wilking N
Innovative treatments for cancer in Europe -Value, cost and access
Lund, Sweden: IHE Report 2016:2
Hofmarcher T, Jönsson B and Wilking N
Access to high-quality oncology care across Europe
Lund, Sweden: IHE Report 2014:2